Eribulin information

Eribulin
Clinical data
Trade names	Halaven, Mevlyq
Other names	E7389, ER-086526, NSC-707389, eribulin mesilate (JAN JP), eribulin mesylate (USAN US)
AHFS/Drugs.com	Monograph
MedlinePlus	a611007
License data	US DailyMed: Eribulin;
Pregnancy; category	AU: D; ;
Routes of; administration	Intravenous
Drug class	Antineoplastic agent
ATC code	L01XX41 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: ℞-only; EU: Rx-only; Rx-only;
Identifiers
	IUPAC name 2-(3-Amino-2-hydroxypropyl)hexacosahydro-3-methoxy- 26-methyl-20,27-bis(methylene)11,15-18,21-24,28-triepoxy- 7,9-ethano-12,15-methano-9H,15H-furo(3,2-i)furo(2',3'-5,6) pyrano(4,3-b)(1,4)dioxacyclopentacosin-5-(4H)-one;
CAS Number	253128-41-5 ;
PubChem CID	11354606;
DrugBank	DB08871 ;
ChemSpider	24721813 ;
UNII	LR24G6354G;
KEGG	D08914;
ChEBI	CHEBI:63587;
ChEMBL	ChEMBL1683590 ;
CompTox Dashboard (EPA)	DTXSID101009321 ;
ECHA InfoCard	100.230.372
Chemical and physical data
Formula	C40H59NO11
Molar mass	729.908 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1CC2CCC3C(=C)CC(O3)CCC45CC6C(O4)C7C(O6)C(O5)C8C(O7)CCC(O8)CC(=O)CC9C(CC(C1=C)O2)OC(C9OC)CC(CN)O;
	InChI InChI=1S/C40H59NO11/c1-19-11-24-5-7-28-20(2)12-26(45-28)9-10-40-17-33-36(51-40)37-38(50-33)39(52-40)35-29(49-37)8-6-25(47-35)13-22(42)14-27-31(16-30(46-24)21(19)3)48-32(34(27)44-4)15-23(43)18-41/h19,23-39,43H,2-3,5-18,41H2,1,4H3/t19-,23+,24+,25-,26+,27+,28+,29+,30-,31+,32-,33-,34-,35+,36+,37+,38-,39+,40+/m1/s1 ; Key:UFNVPOGXISZXJD-JBQZKEIOSA-N ;
	(what is this?) (verify)

Eribulin, sold under the brand name Halaven among others, is an anti-cancer medication used to treat breast cancer and liposarcoma.^[4]^[5]

The most common side effects include fatigue, nausea, hair loss (alopecia), constipation, certain nerve damage causing weakness or numbness in the hands and feet (peripheral neuropathy), abdominal pain and fever (pyrexia).^[10] Eribulin may also cause low levels of infection-fighting white blood cells (neutropenia) or decreased levels of potassium or calcium.^[10]

Eribulin was approved for medical use in the United States in November 2010,^[11] the European Union in March 2011,^[5] and Canada in December 2011.^[2]^[12]^[13] It is available as a generic medication.^[6]

^ "Eribulin (Halaven) Use During Pregnancy". Drugs.com. 22 October 2019. Retrieved 9 July 2020.
^ ^a ^b "Halaven Product information". Health Canada. 22 October 2009. Retrieved 16 December 2023.
^ "Halaven 0.44 mg/ml solution for injection". (emc). 16 January 2023. Retrieved 16 December 2023.
^ ^a ^b "Halaven- eribulin mesylate injection". DailyMed. 22 December 2017. Retrieved 9 July 2020.
^ ^a ^b ^c "Halaven EPAR". European Medicines Agency (EMA). 17 March 2011. Retrieved 16 December 2023.
^ ^a ^b "Mevlyq EPAR". European Medicines Agency (EMA). 9 February 2024. Retrieved 19 February 2024.
^ "Mevlyq product information". Union Register of medicinal products. 13 February 2024. Retrieved 19 February 2024.
^ "Eisai Announces Japan Launch Of Anticancer Agent Halaven" (Press release). Eisai Co., Ltd. 19 July 2011. Retrieved 15 February 2021.
^ "Anticancer Agent Halaven Approved For Treatment Of Locally Advanced Or Metastatic Breast Cancer In China" (Press release). Eisai Co., Ltd. 17 July 2019. Retrieved 15 February 2021.
^ ^a ^b Cite error: The named reference FDA-lipo2016 was invoked but never defined (see the help page).
^ "Drug Approval Package: Halaven (erbulin mesylate) NDA 201532". U.S. Food and Drug Administration (FDA). Retrieved 9 July 2020.
^ "Halaven for Metastatic Breast Cancer". Canadian Agency for Drugs and Technologies in Health. 9 March 2015. Retrieved 9 July 2020.
^ "Eisai Announces Canadian Approval of its Anticancer Agent Halaven". Eisai Co., Ltd. (Press release). Retrieved 9 July 2020.

[Drugs.com_pregnancy-1] "Eribulin (Halaven) Use During Pregnancy". Drugs.com. 22 October 2019. Retrieved 9 July 2020.

[CA_Halaven_PI-2] "Halaven Product information". Health Canada. 22 October 2009. Retrieved 16 December 2023.

[3] "Halaven 0.44 mg/ml solution for injection". (emc). 16 January 2023. Retrieved 16 December 2023.

[Halaven_FDA_label-4] "Halaven- eribulin mesylate injection". DailyMed. 22 December 2017. Retrieved 9 July 2020.

[Halaven_EPAR-5] "Halaven EPAR". European Medicines Agency (EMA). 17 March 2011. Retrieved 16 December 2023.

[Mevlyq_EPAR-6] "Mevlyq EPAR". European Medicines Agency (EMA). 9 February 2024. Retrieved 19 February 2024.

[7] "Mevlyq product information". Union Register of medicinal products. 13 February 2024. Retrieved 19 February 2024.

[8] "Eisai Announces Japan Launch Of Anticancer Agent Halaven" (Press release). Eisai Co., Ltd. 19 July 2011. Retrieved 15 February 2021.

[9] "Anticancer Agent Halaven Approved For Treatment Of Locally Advanced Or Metastatic Breast Cancer In China" (Press release). Eisai Co., Ltd. 17 July 2019. Retrieved 15 February 2021.

[FDA-lipo2016-10] Cite error: The named reference FDA-lipo2016 was invoked but never defined (see the help page).

[11] "Drug Approval Package: Halaven (erbulin mesylate) NDA 201532". U.S. Food and Drug Administration (FDA). Retrieved 9 July 2020.

[12] "Halaven for Metastatic Breast Cancer". Canadian Agency for Drugs and Technologies in Health. 9 March 2015. Retrieved 9 July 2020.

[13] "Eisai Announces Canadian Approval of its Anticancer Agent Halaven". Eisai Co., Ltd. (Press release). Retrieved 9 July 2020.

Eribulin information

and 26 Related for: Eribulin information

Eribulin

Halichondrin B

Halozyme

Tretinoin

Trastuzumab deruxtecan

Methotrexate

Sponge

Bioprospecting

Tetrahydrofuran

Microtubule

Fuzuloparib

Vincristine

Carboplatin

Cytarabine

Fluorouracil

Olaparib

Hydroxycarbamide

Celecoxib

Liposarcoma

Ribociclib

Doxorubicin

Temozolomide

Tebentafusp

Alkylating antineoplastic agent

Marine pharmacognosy

Idarubicin